Abstract
A review With the successful application of convalescent plasma (CP) in various acute viral infectious diseases the unique advantage of the therapy has been paid more and more attentions Recently, a novel coronavirus named as SARS-CoV-2 was discovered and identified in Wuhan, China Up to now, there has been no specific treatment for 2019-nCoV (SARS-CoV-2) infection This paper describes the current status of application of CP in Ebola, pandemic in influenza severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) as well as the prospect of CP in therapy of COVID-19
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Biologicals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
